In the spring of 2020, when the Covid-19 epidemic intensified, many pharmaceutical companies faced disruptions in their supply chain. Chemicals used in the manufacture of key ingredients in medicines were often sourced from individual suppliers in China – sometimes only one supplier.
The epidemic has revealed how dependent the global drug supply chain is on China, even for the most basic ingredients.
This is the final episode in the Nikkei Asia series about the goal of Beijing to become the center of the global pharmaceutical industry. This chapter focuses on China’s market command of active pharmaceutical ingredients – a dominance that some Western countries challenge since Cubid-19 and geopolitical tensions reveal supply chain vulnerabilities.
read more Here.
A version of this article First published by Nikkei Asia April 5, 2022. © 2022 Nikkei Inc. All rights reserved
This article is from Nike Asia, A global publication with a unique Asian perspective on politics, economics, business and international affairs. Our reporters and outside commentators from around the world share their views on Asia, while our Asia300 section provides in-depth coverage of 300 of the largest and growing companies listed in more than 11 economies outside of Japan.
The great medicines migration: how China controls key drug supplies Source link The great medicines migration: how China controls key drug supplies